Ofatumumab is a feasible alternative anti‐CD20 therapy in patients intolerant of rituximab von Chen, Lucia Y., Shah, Raakhee, Cwynarski, Kate, Lambert, Jonathan, McNamara, Christopher, Mohamedbhai, Sajir G., Virchis, Andres, Townsend, William, D'Sa, Shirley, Ardeshna, Kirit M.

Volltext

Predominant or complete recipient T-cell chimerism following alemtuzumab-based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failure von Mohamedbhai, Sajir G., Edwards, Noha, Morris, Emma C., Mackinnon, Stephen, Thomson, Kirsty J., Peggs, Karl S.

Volltext

Rituximab in combination with CODOX‐M/IVAC: a retrospective analysis of 23 cases of non‐HIV related B‐cell non‐Hodgkin lymphoma with proliferation index >95 von Mohamedbhai, Sajir G., Sibson, Keith, Marafioti, Teresa, Kayani, Irfan, Lowry, Lisa, Goldstone, Anthony H., Linch, David C., Ardeshna, Kirit M.

Volltext

Ofatumumab is a feasible alternative anti‐ CD 20 therapy in patients intolerant of rituximab von Chen, Lucia Y., Shah, Raakhee, Cwynarski, Kate, Lambert, Jonathan, McNamara, Christopher, Mohamedbhai, Sajir G., Virchis, Andres, Townsend, William, D'Sa, Shirley, Ardeshna, Kirit M.

Volltext